Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - NRBF2 FGFR2 N549K||cholangiocarcinoma||predicted - resistant||Pemigatinib||Case Reports/Case Series||Actionable||In a Phase II trial (FIGHT-202), a cholangiocarcinoma patient harboring FGFR2-NRBF2 experienced disease progression after 13.1 months of treatment with Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K (PMID: 33218975; NCT02924376).||33218975|